<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="eliminate">
<roleset id="eliminate.01" name="remove
" wordnet="1">
<roles>
  <role n="0" descr="entity removing
"/>
  <role n="1" descr="thing being removed
"/>
  <role n="2" descr="removed from
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
One of the remaining three families carried a 3-bp in-frame deletion that would eliminate an asparagine residue within a kinase domain of the product; the other two carried intronic mutations at or adjacent to the consensus dinucleotide sequences of splice-acceptor or-donor sites, which were likely to lead to aberrant splicing.

</text>
       <arg n="0">a 3-bp in-frame deletion
</arg>
       <arg n="1">an asparagine residue 
</arg>
       <arg n="2">[within] a kinase domain of the product
</arg>
       <arg n="M-MOD">would
</arg>
<fdg>

1	One	one	subj:&gt;7	@SUBJ %NH NUM CARD
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	the	the	det:&gt;6	@DN&gt; %&gt;N DET
4	remaining	remaining	attr:&gt;5	@A&gt; %&gt;N A ABS
5	three	three	qn:&gt;6	@QN&gt; %&gt;N NUM CARD
6	families	family	pcomp:&gt;2	@&lt;P %NH N NOM PL
7	carried	carry	main:&gt;0	@+FMAINV %VA V PAST
8	a	a	det:&gt;11	@DN&gt; %&gt;N DET SG
9	3-bp	3-bp	attr:&gt;10	@A&gt; %&gt;N &lt;?&gt; N NOM SG
10	in-frame	in-frame	attr:&gt;11	@A&gt; %&gt;N &lt;?&gt; A ABS
11	deletion	deletion	obj:&gt;7	@OBJ %NH N NOM SG
12	that	that	subj:&gt;13	@SUBJ %NH &lt;Rel&gt; PRON
13	would	would	v-ch:&gt;14	@+FAUXV %AUX V AUXMOD
14	eliminate	eliminate	mod:&gt;11	@-FMAINV %VA V INF
15	an	an	det:&gt;17	@DN&gt; %&gt;N DET SG
16	asparagine	asparagine	attr:&gt;17	@A&gt; %&gt;N &lt;?&gt; N NOM SG
17	residue	residue	obj:&gt;14	@OBJ %NH N NOM SG
18	within	within	ha:&gt;14	@ADVL %EH PREP
19	a	a	det:&gt;21	@DN&gt; %&gt;N DET SG
20	kinase	kinase	attr:&gt;21	@A&gt; %&gt;N N NOM SG
21	domain	domain	pcomp:&gt;18	@&lt;P %NH N NOM SG
22	of	of	mod:&gt;21	@&lt;NOM-OF %N&lt; PREP
23	the	the	det:&gt;24	@DN&gt; %&gt;N DET
24	product	product	pcomp:&gt;22	@&lt;P %NH N NOM SG
25	;	;
26	the	the	det:&gt;28	@DN&gt; %&gt;N DET
27	other	other		@DN&gt; %&gt;N DET
28	two	two		@NH %NH NUM CARD	@SUBJ %NH NUM CARD
29	carried	carried	attr:&gt;30	@A&gt; %&gt;N A ABS
30	intronic	intronic	attr:&gt;31	@A&gt; %&gt;N &lt;?&gt; A ABS
31	mutations	mutation		@NH %NH N NOM PL	@SUBJ %NH N NOM PL
32	at	at		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
33	or	or		@CC %CC CC
34	adjacent	adjacent		@SUBJ %NH A ABS	@OBJ %NH A ABS	@&lt;NOM %N&lt; A ABS	@NH %NH A ABS
35	to	to	mod:&gt;34	@&lt;NOM %N&lt; PREP
36	the	the	det:&gt;39	@DN&gt; %&gt;N DET
37	consensus	consensus	attr:&gt;38	@A&gt; %&gt;N N NOM SG
38	dinucleotide	dinucleotide	attr:&gt;39	@A&gt; %&gt;N N NOM SG
39	sequences	sequence	pcomp:&gt;35	@&lt;P %NH N NOM PL
40	of	of	mod:&gt;39	@&lt;NOM-OF %N&lt; PREP
41	splice-acceptor	splice-acceptor	pcomp:&gt;40	@&lt;P %NH &lt;?&gt; N NOM SG
42	or	or		@CC %CC CC
43	-	-
44	donor	donor	attr:&gt;45	@A&gt; %&gt;N N NOM SG
45	sites	site		@NH %NH N NOM PL	@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL	@PCOMPL-S 

%NH N NOM PL	@APP %NH N NOM PL	@&lt;P %NH N NOM PL
46	,	,
47	which	which	subj:&gt;48	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
48	were	be	mod:&gt;45	@+FMAINV %VA V PAST PL
49	likely	likely	comp:&gt;48	@PCOMPL-S %NH A ABS
50	to	to	pm:&gt;51	@INFMARK&gt; %AUX INFMARK&gt;
51	lead	lead	mod:&gt;49	@-FMAINV %VA V INF
52	to	to	ha:&gt;51	@ADVL %EH PREP
53	aberrant	aberrant	attr:&gt;54	@A&gt; %&gt;N A ABS
54	splicing	splicing	pcomp:&gt;52	@&lt;P %NH N NOM SG
55	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
One mutation eliminates the BamHI site in exon 7 and the other eliminates the HindIII site in exon 11 of the phenylalanine hydroxylase gene. 

</text>
       <arg n="0">One mutation
</arg>
       <arg n="1">the BamHI site
</arg>
       <arg n="2">[in] exon 7
</arg>
<fdg>
1	One	one	qn:&gt;2	@QN&gt; %&gt;N NUM CARD
2	mutation	mutation	subj:&gt;3	@SUBJ %NH N NOM SG
3	eliminates	eliminate	main:&gt;0	@+FMAINV %VA V PRES SG3
4	the	the	det:&gt;6	@DN&gt; %&gt;N DET
5	BamHI	bamhi	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	site	site	obj:&gt;3	@OBJ %NH N NOM SG
7	in	in	mod:&gt;6	@&lt;NOM %N&lt; PREP
8	exon	exon	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	7	7	pcomp:&gt;7	@&lt;P %NH NUM CARD
10	and	and	cc:&gt;3	@CC %CC CC
11	the	the	det:&gt;12	@DN&gt; %&gt;N DET
12	other	other	subj:&gt;13	@SUBJ %NH PRON NOM SG
13	eliminates	eliminate	cc:&gt;3	@+FMAINV %VA V PRES SG3
14	the	the	det:&gt;16	@DN&gt; %&gt;N DET
15	HindIII	hindiii	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	site	site	obj:&gt;13	@OBJ %NH N NOM SG
17	in	in	mod:&gt;16	@&lt;NOM %N&lt; PREP
18	exon	exon	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	11	11	pcomp:&gt;17	@&lt;P %NH NUM CARD
20	of	of	mod:&gt;19	@&lt;NOM-OF %N&lt; PREP
21	the	the	det:&gt;24	@DN&gt; %&gt;N DET
22	phenylalanine	phenylalanine	attr:&gt;23	@A&gt; %&gt;N &lt;?&gt; N NOM SG
23	hydroxylase	hydroxylase	attr:&gt;24	@A&gt; %&gt;N &lt;?&gt; N NOM SG
24	gene	gene	pcomp:&gt;20	@&lt;P %NH N NOM SG
25	.     .
</fdg>
</example>
<example src="MEDLINE" no="3">
<text>
One mutation eliminates the BamHI site in exon 7 and the other eliminates the HindIII site in exon 11 of the phenylalanine hydroxylase gene. 

</text>
       <arg n="0">the other
</arg>
       <arg n="1">the HindIII site 
</arg>
       <arg n="2">[in] exon 11 of the phenylalanine hydroxylase gene
</arg>
<fdg>
1	One	one	qn:&gt;2	@QN&gt; %&gt;N NUM CARD
2	mutation	mutation	subj:&gt;3	@SUBJ %NH N NOM SG
3	eliminates	eliminate	main:&gt;0	@+FMAINV %VA V PRES SG3
4	the	the	det:&gt;6	@DN&gt; %&gt;N DET
5	BamHI	bamhi	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	site	site	obj:&gt;3	@OBJ %NH N NOM SG
7	in	in	mod:&gt;6	@&lt;NOM %N&lt; PREP
8	exon	exon	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	7	7	pcomp:&gt;7	@&lt;P %NH NUM CARD
10	and	and	cc:&gt;3	@CC %CC CC
11	the	the	det:&gt;12	@DN&gt; %&gt;N DET
12	other	other	subj:&gt;13	@SUBJ %NH PRON NOM SG
13	eliminates	eliminate	cc:&gt;3	@+FMAINV %VA V PRES SG3
14	the	the	det:&gt;16	@DN&gt; %&gt;N DET
15	HindIII	hindiii	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	site	site	obj:&gt;13	@OBJ %NH N NOM SG
17	in	in	mod:&gt;16	@&lt;NOM %N&lt; PREP
18	exon	exon	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	11	11	pcomp:&gt;17	@&lt;P %NH NUM CARD
20	of	of	mod:&gt;19	@&lt;NOM-OF %N&lt; PREP
21	the	the	det:&gt;24	@DN&gt; %&gt;N DET
22	phenylalanine	phenylalanine	attr:&gt;23	@A&gt; %&gt;N &lt;?&gt; N NOM SG
23	hydroxylase	hydroxylase	attr:&gt;24	@A&gt; %&gt;N &lt;?&gt; N NOM SG
24	gene	gene	pcomp:&gt;20	@&lt;P %NH N NOM SG
25	.     .
</fdg>
</example>
<example src="MEDLINE" no="4">
<text>
They establish that inhibition of any one of these molecules, as may occur following caspase activation, could eliminate vital stem cells required for skeletal muscle regeneration during chronic catabolic conditions.

</text>
       <arg n="0">inhibition of any one of these molecules 
</arg>
       <arg n="1">vital stem cells 
</arg>
       <arg n="2">-
</arg>
<fdg>
1	They	they	subj:&gt;2	@SUBJ %NH PRON PERS NOM PL3
2	establish	establish	main:&gt;0	@+FMAINV %VA V PRES
3	that	that	det:&gt;4	@DN&gt; %&gt;N DET DEM SG
4	inhibition	inhibition	obj:&gt;2	@OBJ %NH N NOM SG
5	of	of	mod:&gt;4	@&lt;NOM-OF %N&lt; PREP
6	any one	any one	pcomp:&gt;5	@&lt;P %NH PRON NOM SG
7	of	of	mod:&gt;6	@&lt;NOM-OF %N&lt; PREP
8	these	this	det:&gt;9	@DN&gt; %&gt;N DET DEM PL
9	molecules	molecule	pcomp:&gt;7	@&lt;P %NH N NOM PL
10	,	,
11	as	as		@CS %CS CS
12	may	may	v-ch:&gt;13	@+FAUXV %AUX V AUXMOD
13	occur	occur		@-FMAINV %VA V INF
14	following	follow		@-FMAINV %VA ING
15	caspase	caspase	attr:&gt;16	@A&gt; %&gt;N &lt;?&gt; N NOM SG
16	activation	activation	obj:&gt;14	@OBJ %NH N NOM SG
17	,	,
18	could	could	v-ch:&gt;19	@+FAUXV %AUX V AUXMOD
19	eliminate	eliminate		@-FMAINV %VA V INF
20	vital	vital	attr:&gt;21	@A&gt; %&gt;N A ABS
21	stem	stem	attr:&gt;22	@A&gt; %&gt;N N NOM SG
22	cells	cell	obj:&gt;19	@OBJ %NH N NOM PL
23	required	require	mod:&gt;22	@-FMAINV %VP EN
24	for	for	ha:&gt;23	@ADVL %EH PREP
25	skeletal	skeletal	attr:&gt;26	@A&gt; %&gt;N A ABS
26	muscle	muscle	attr:&gt;27	@A&gt; %&gt;N N NOM SG
27	regeneration	regeneration	pcomp:&gt;24	@&lt;P %NH N NOM SG
28	during	during	mod:&gt;27	@&lt;NOM %N&lt; PREP
29	chronic	chronic	attr:&gt;30	@A&gt; %&gt;N A ABS
30	catabolic	catabolic	attr:&gt;31	@A&gt; %&gt;N A ABS
31	conditions	condition	pcomp:&gt;28	@&lt;P %NH N NOM PL
32	.     .
</fdg>
</example>
<example src="MEDLINE" no="5">
<text>
This occurs by microbe-detecting receptors activating immune cells to eliminate the pathogens.

</text>
       <arg n="0">microbe-detecting receptors activating immune cells
</arg>
       <arg n="1">the pathogens
</arg>
       <arg n="2">-
</arg>
<fdg>
1	This	this	subj:&gt;2	@SUBJ %NH PRON DEM SG
2	occurs	occur	main:&gt;0	@+FMAINV %VA V PRES SG3
3	by	by	ha:&gt;2	@ADVL %EH PREP
4	microbe-detecting	microbe-detecting	attr:&gt;5	@A&gt; %&gt;N &lt;?&gt; A ABS
5	receptors	receptor	pcomp:&gt;3	@&lt;P %NH N NOM PL
6	,	,
7	such	such	mod:&gt;5	@APP %NH PRON NOM
8	as	as	mod:&gt;7	@ADVL %EH PREP
9	CD14	cd14	pcomp:&gt;8	@&lt;P %NH N NOM SG
10	,	,
11	that	that	subj:&gt;12	@SUBJ %NH &lt;Rel&gt; PRON
12	activate	activate	mod:&gt;9	@+FMAINV %VA V PRES
13	immune	immune	attr:&gt;14	@A&gt; %&gt;N A ABS
14	cells	cell	obj:&gt;12	@OBJ %NH N NOM PL
15	to	to	pm:&gt;16	@INFMARK&gt; %AUX INFMARK&gt;
16	eliminate	eliminate	mod:&gt;14	@-FMAINV %VA V INF
17	the	the	det:&gt;18	@DN&gt; %&gt;N DET
18	pathogens	pathogen	obj:&gt;16	@OBJ %NH N NOM PL
19	.     .
</fdg>
</example>
<example src="MEDLINE" no="6">
<text>
Transgenic plants expressing AtNDK1 under control of the CaMV 35S promoter exhibited tolerance to paraquat and high ability to eliminate exogenous H(2)O(2).

</text>
       <arg n="0">
</arg>
       <arg n="1">exogenous H(2)O(2)
</arg>
       <arg n="2">Transgenic plants
</arg>
<fdg>
1	Transgenic	transgenic	attr:&gt;2	@A&gt; %&gt;N A ABS
2	plants	plant		@NH %NH N NOM PL	@SUBJ %NH N NOM PL
3	expressing	express		@-FMAINV %VA ING
4	AtNDK1	atndk1	obj:&gt;3	@OBJ %NH N NOM SG
5	under	under	loc:&gt;3	@ADVL %EH PREP
6	control	control	pcomp:&gt;5	@&lt;P %NH N NOM SG
7	of	of	mod:&gt;6	@&lt;NOM-OF %N&lt; PREP
8	the	the	det:&gt;11	@DN&gt; %&gt;N DET
9	CaMV	camv		@A&gt; %&gt;N N NOM SG
10	35S	35s	qn:&gt;11	@QN&gt; %&gt;N NUM CARD
11	promoter	promoter	pcomp:&gt;7	@&lt;P %NH N NOM SG
12	exhibited	exhibit		@+FMAINV %VA V PAST
13	tolerance	tolerance	obj:&gt;12	@OBJ %NH N NOM SG
14	to	to	goa:&gt;12	@ADVL %EH PREP
15	paraquat	paraquat	pcomp:&gt;14	@&lt;P %NH N NOM SG
16	and	and	cc:&gt;15	@CC %CC CC
17	high	high	attr:&gt;18	@A&gt; %&gt;N A ABS
18	ability	ability	cc:&gt;15	@&lt;P %NH N NOM SG
19	to	to	pm:&gt;20	@INFMARK&gt; %AUX INFMARK&gt;
20	eliminate	eliminate	mod:&gt;18	@-FMAINV %VA V INF
21	exogenous	exogenous	attr:&gt;22	@A&gt; %&gt;N A ABS
22	H(2)O(2)	h(2)o(2)	obj:&gt;20	@OBJ %NH N NOM SG
23	.     .
</fdg>
</example>
<example src="MEDLINE" no="7">
<text>
To eliminate any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes.

</text>
       <arg n="0">-
</arg>
       <arg n="1">any deleterious effects
</arg>
       <arg n="2">-
</arg>
<fdg>
1	To	to	pm:&gt;2	@INFMARK&gt; %AUX INFMARK&gt;
2	eliminate	eliminate	cnt:&gt;20	@-FMAINV %VA V INF
3	any	any	det:&gt;5	@DN&gt; %&gt;N DET
4	deleterious	deleterious	attr:&gt;5	@A&gt; %&gt;N A ABS
5	effects	effect	obj:&gt;2	@OBJ %NH N NOM PL
6	that	that	subj:&gt;7	@SUBJ %NH &lt;Rel&gt; PRON
7	might	might	v-ch:&gt;8	@+FAUXV %AUX V AUXMOD
8	be	be	v-ch:&gt;9	@-FAUXV %AUX V INF
9	associated	associate	mod:&gt;5	@-FMAINV %VP EN
10	with	with	phr:&gt;9	@ADVL %EH PREP
11	stable	stable	attr:&gt;12	@A&gt; %&gt;N A ABS
12	HOXB4	hoxb4	attr:&gt;13	@A&gt; %&gt;N N NOM SG
13	gene	gene	attr:&gt;14	@A&gt; %&gt;N N NOM SG
14	transfer	transfer	pcomp:&gt;10	@&lt;P %NH N NOM SG
15	into	into	goa:&gt;9	@ADVL %EH PREP
16	human	human	attr:&gt;17	@A&gt; %&gt;N A ABS
17	cells	cell	pcomp:&gt;15	@&lt;P %NH N NOM PL
18	,	,
19	we	we	subj:&gt;20	@SUBJ %NH PRON PERS NOM PL1
20	took	take	main:&gt;0	@+FMAINV %VA V PAST
21	advantage	advantage	obj:&gt;20	@OBJ %NH N NOM SG
22	of	of	mod:&gt;21	@&lt;NOM-OF %N&lt; PREP
23	the	the	det:&gt;24	@DN&gt; %&gt;N DET
24	ability	ability	pcomp:&gt;22	@&lt;P %NH N NOM SG
25	of	of	mod:&gt;24	@&lt;NOM-OF %N&lt; PREP
26	HOX	hox	attr:&gt;27	@A&gt; %&gt;N N NOM SG
27	proteins	protein	pcomp:&gt;25	@&lt;P %NH N NOM PL
28	to	to	pm:&gt;30	@INFMARK&gt; %AUX INFMARK&gt;
29	passively	passively	man:&gt;30	@ADVL %EH ADV
30	translocate	translocate	mod:&gt;27	@-FMAINV %VA V INF
31	through	through	ha:&gt;30	@ADVL %EH PREP
32	cell	cell	attr:&gt;33	@A&gt; %&gt;N N NOM SG
33	membranes	membrane	pcomp:&gt;31	@&lt;P %NH N NOM PL
34	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
Addition of Grb2 significantly reduced SH3A binding to mSos1 in a concent rat ion-dependent manner, with binding completely eliminated at a molar ratio of 5:1 (Figure 7).

</text>
       <arg n="0">at a molar ratio of 5:1 
</arg>
       <arg n="1">binding 
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Addition	addition	subj:&gt;5	@SUBJ %NH N NOM SG
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	Grb2	grb2	pcomp:&gt;2	@&lt;P %NH N NOM SG
4	significantly	significantly		@ADVL %EH ADV	@AD-A&gt; %E&gt; ADV
5	reduced	reduce	main:&gt;0	@+FMAINV %VA V PAST
6	SH3A	sh3a	obj:&gt;5	@OBJ %NH N NOM SG
7	binding	bind	mod:&gt;6	@-FMAINV %VA ING
8	to	to	ha:&gt;7	@ADVL %EH PREP
9	mSos1	msos1	pcomp:&gt;8	@&lt;P %NH N NOM SG
10	in	in		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
11	a	a	det:&gt;15	@DN&gt; %&gt;N DET SG
12	concent	concent	attr:&gt;13	@A&gt; %&gt;N &lt;?&gt; N NOM SG
13	rat	rat	attr:&gt;14	@A&gt; %&gt;N N NOM SG
14	ion-dependent	ion-dependent	attr:&gt;15	@A&gt; %&gt;N &lt;?&gt; A ABS
15	manner	manner	pcomp:&gt;10	@&lt;P %NH N NOM SG
16	,	,
17	with	with		@ADVL %EH PREP
18	binding	bind	pcomp:&gt;17	@&lt;P-FMAINV %VA ING
19	completely	completely	man:&gt;18	@ADVL %EH ADV
20	eliminated	eliminate		@-FMAINV %VP EN
21	at	at	ha:&gt;20	@ADVL %EH PREP
22	a	a	det:&gt;24	@DN&gt; %&gt;N DET SG
23	molar	molar	attr:&gt;24	@A&gt; %&gt;N N NOM SG
24	ratio	ratio	pcomp:&gt;21	@&lt;P %NH N NOM SG
25	of	of	mod:&gt;24	@&lt;NOM-OF %N&lt; PREP
26	5:1	5:1	pcomp:&gt;25	@&lt;P %NH NUM CARD
27	(	(
28	Figure	figure		@NH %NH N NOM SG	@APP %NH N NOM SG	@A&gt; %&gt;N N NOM SG
29	7	7		@NH %NH NUM CARD	@APP %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
30	)	)
31	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
Eliminating the inhibitory phosphorylation or mimicking activating phosphorylation sites is sufficient to confer constitutive activity upon lin-45 Raf and induce multi-vulva phenotypes in C.elegans.

</text>
       <arg n="0">-
</arg>
       <arg n="1">the inhibitory phosphorylation
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Eliminating	eliminate		@-FMAINV %VA ING
2	the	the	det:&gt;4	@DN&gt; %&gt;N DET
3	inhibitory	inhibitory	attr:&gt;4	@A&gt; %&gt;N A ABS
4	phosphorylation	phosphorylation	obj:&gt;1	@OBJ %NH N NOM SG
5	or	or		@CC %CC CC
6	mimicking	mimicking		@A&gt; %&gt;N A ABS	@APP %NH A ABS	@SUBJ %NH A ABS	@OBJ %NH A ABS	@&lt;NOM %N&lt; A ABS	@-FMAINV %VA ING
7	activating	activating		@A&gt; %&gt;N A ABS	@-FMAINV %VA ING
8	phosphorylation	phosphorylation	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	sites	site		@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL	@PCOMPL-S %NH N NOM PL
10	is	be		@+FMAINV %VA V PRES SG3
11	sufficient	sufficient	comp:&gt;10	@PCOMPL-S %NH A ABS
12	to	to	pm:&gt;13	@INFMARK&gt; %AUX INFMARK&gt;
13	confer	confer	mod:&gt;11	@-FMAINV %VA V INF
14	constitutive	constitutive	attr:&gt;15	@A&gt; %&gt;N A ABS
15	activity	activity	obj:&gt;13	@OBJ %NH N NOM SG
16	upon	upon	ha:&gt;13	@ADVL %EH PREP
17	lin-45	lin-45		@QN&gt; %&gt;N &lt;?&gt; NUM CARD
18	Raf	raf	pcomp:&gt;16	@&lt;P %NH N NOM SG
19	and	and	cc:&gt;13	@CC %CC CC
20	induce	induce	cc:&gt;13	@-FMAINV %VA V INF
21	multi-vulva	multi-vulva	attr:&gt;22	@A&gt; %&gt;N &lt;?&gt; A ABS
22	phenotypes	phenotype	obj:&gt;20	@OBJ %NH N NOM PL
23	in	in	loc:&gt;20	@ADVL %EH PREP
24	C.elegans	c.elegans	pcomp:&gt;23	@&lt;P %NH N NOM SG
25	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
Mutation of T491 eliminated the recognition by the anti-pT598 antibody while mutation at S494 had no effect (Figure 2C).

</text>
       <arg n="0">Mutation of T491
</arg>
       <arg n="1">the recognition by the anti-pT598 antibody
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Mutation	mutation	subj:&gt;4	@SUBJ %NH N NOM SG
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	T491	t491	pcomp:&gt;2	@&lt;P %NH N NOM SG
4	eliminated	eliminate	main:&gt;0	@+FMAINV %VA V PAST
5	the	the	det:&gt;6	@DN&gt; %&gt;N DET
6	recognition	recognition	obj:&gt;4	@OBJ %NH N NOM SG
7	by	by	ha:&gt;4	@ADVL %EH PREP
8	the	the	det:&gt;10	@DN&gt; %&gt;N DET
9	anti-pT598	anti-pt598		@QN&gt; %&gt;N &lt;?&gt; NUM CARD
10	antibody	antibody	pcomp:&gt;7	@&lt;P %NH N NOM SG
11	while	while	tmp:&gt;15	@ADVL %EH ADV WH
12	mutation	mutation	subj:&gt;15	@SUBJ %NH N NOM SG
13	at	at	mod:&gt;12	@&lt;NOM %N&lt; PREP
14	S494	s494	pcomp:&gt;13	@&lt;P %NH N NOM SG
15	had	have	tmp:&gt;4	@+FMAINV %VA V PAST
16	no	no	det:&gt;17	@DN&gt; %&gt;N DET
17	effect	effect	obj:&gt;15	@OBJ %NH N NOM SG
18	(	(
19	Figure	figure		@A&gt; %&gt;N N NOM SG
20	2C	2c	qua:&gt;15	@ADVL %EH NUM CARD
21	)	)
22	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
The same high level of activation of B-Raf occurs only when all three sites are eliminated.

</text>
       <arg n="0">-
</arg>
       <arg n="1">all three sites
</arg>
       <arg n="2">-
</arg>
<fdg>
1	The	the	det:&gt;4	@DN&gt; %&gt;N DET
2	same	same	attr:&gt;3	@A&gt; %&gt;N A ABS
3	high	high	attr:&gt;4	@A&gt; %&gt;N A ABS
4	level	level	subj:&gt;9	@SUBJ %NH N NOM SG
5	of	of	mod:&gt;4	@&lt;NOM-OF %N&lt; PREP
6	activation	activation	pcomp:&gt;5	@&lt;P %NH N NOM SG
7	of	of	mod:&gt;6	@&lt;NOM-OF %N&lt; PREP
8	B-Raf	b-raf	pcomp:&gt;7	@&lt;P %NH N NOM SG
9	occurs	occur	main:&gt;0	@+FMAINV %VA V PRES SG3
10	only	only	meta:&gt;14	@ADVL %EH ADV
11	when	when	tmp:&gt;16	@ADVL %EH ADV WH
12	all	all	det:&gt;14	@DN&gt; %&gt;N DET
13	three	three	qn:&gt;14	@QN&gt; %&gt;N NUM CARD
14	sites	site	subj:&gt;15	@SUBJ %NH N NOM PL
15	are	be	v-ch:&gt;16	@+FAUXV %AUX V PRES
16	eliminated	eliminate	tmp:&gt;9	@-FMAINV %VP EN
17	.     .
</fdg>
</example>
<example src="EMBO" no="5">
<text>
Secondly, SBP2 binding activity is not affected by mutations in the tetra-adenosine element in the terminal region of the PHGPx 3 UTR, yet these same mutations completely eliminate Sec incorporation (Lesoon et al., 1997).

</text>
       <arg n="0">these same mutations
</arg>
       <arg n="1">Sec incorporation
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Secondly	secondly		@ADVL %EH ADV
2	,	,
3	SBP2	sbp2	subj:&gt;6	@SUBJ %NH N NOM SG
4	binding	bind	mod:&gt;3	@-FMAINV %VA ING
5	activity	activity	obj:&gt;4	@OBJ %NH N NOM SG
6	is	be	v-ch:&gt;8	@+FAUXV %AUX V PRES SG3
7	not	not	neg:&gt;6	@ADVL %EH NEG-PART
8	affected	affect		@-FMAINV %VP EN
9	by	by	agt:&gt;8	@ADVL %EH PREP
10	mutations	mutation	pcomp:&gt;9	@&lt;P %NH N NOM PL
11	in	in	mod:&gt;10	@&lt;NOM %N&lt; PREP
12	the	the	det:&gt;14	@DN&gt; %&gt;N DET
13	tetra-adenosine	tetra-adenosine	attr:&gt;14	@A&gt; %&gt;N &lt;?&gt; N NOM SG
14	element	element	pcomp:&gt;11	@&lt;P %NH N NOM SG
15	in	in	mod:&gt;14	@&lt;NOM %N&lt; PREP
16	the	the	det:&gt;18	@DN&gt; %&gt;N DET
17	terminal	terminal	attr:&gt;18	@A&gt; %&gt;N A ABS
18	region	region	pcomp:&gt;15	@&lt;P %NH N NOM SG
19	of	of	mod:&gt;18	@&lt;NOM-OF %N&lt; PREP
20	the	the	det:&gt;21	@DN&gt; %&gt;N DET
21	PHGPx	phgpx	pcomp:&gt;19	@&lt;P %NH N NOM SG
22	3	3	qn:&gt;24	@QN&gt; %&gt;N NUM CARD
23	&apos;	&apos;
24	UTR	utr		@SUBJ %NH N NOM SG
25	,	,
26	yet	yet	cc:&gt;8	@CC %CC CC
27	these	this	det:&gt;29	@DN&gt; %&gt;N DET DEM PL
28	same	same	attr:&gt;29	@A&gt; %&gt;N A ABS
29	mutations	mutation	subj:&gt;31	@SUBJ %NH N NOM PL
30	completely	completely	man:&gt;31	@ADVL %EH ADV
31	eliminate	eliminate	cc:&gt;8	@+FMAINV %VA V PRES
32	Sec	sec	attr:&gt;33	@A&gt; %&gt;N ABBR NOM SG
33	incorpo	incorpo	attr:&gt;34	@A&gt; %&gt;N &lt;?&gt; N NOM SG
34	ration	ration	obj:&gt;31	@OBJ %NH N NOM SG
35	(	(
36	Lesoon	lesoon	main:&gt;35	@APP %NH &lt;?&gt; N NOM SG
37	et	et		@CC %CC CC
38	al.	al.		@SUBJ %NH ABBR NOM SG	@OBJ %NH ABBR NOM SG	@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG	@ADVL %EH ABBR NOM SG
39	,	,
40	1997	1997		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
41	)	)
42	.     .
</fdg>
</example>
<example src="EMBO" no="6">
<text>
As illustrated in Figure 1, staurosporin (or genestein; data not shown) did not eliminate the stabilization seen with MG132.

</text>
       <arg n="0">staurosporin (or genestein; data not shown)
</arg>
       <arg n="1">the stabilization seen with MG132
</arg>
       <arg n="2">-
</arg>
       <arg n="M-NEG">not
</arg>
<fdg>

1	As	as	pm:&gt;2	@CS %CS CS
2	illustrated	illustrate	cla:&gt;18	@-FMAINV %VP EN
3	in	in	ha:&gt;2	@ADVL %EH PREP
4	Figure	figure	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	1	1	pcomp:&gt;3	@&lt;P %NH NUM CARD
6	,	,
7	staurosporin	staurosporin	subj:&gt;16	@SUBJ %NH &lt;?&gt; N NOM SG
8	(	(
9	or	or	cc:&gt;8	@CC %CC CC
10	genestein	genestein		@SUBJ %NH &lt;?&gt; N NOM SG	@OBJ %NH &lt;?&gt; N NOM SG	@PCOMPL-O %NH &lt;?&gt; N NOM SG	@APP %NH &lt;?&gt; N NOM SG
11	;	;
12	data	data	mod:&gt;10	@NH %NH N NOM
13	not	not	neg:&gt;14	@ADVL %EH NEG-PART
14	shown	show	mod:&gt;12	@-FMAINV %VP EN
15	)	)
16	did	do	v-ch:&gt;18	@+FAUXV %AUX V PAST
17	not	not	neg:&gt;16	@ADVL %EH NEG-PART
18	eliminate	eliminate	main:&gt;0	@-FMAINV %VA V INF
19	the	the	det:&gt;20	@DN&gt; %&gt;N DET
20	stabilization	stabilization	obj:&gt;18	@OBJ %NH N NOM SG
21	seen	see	mod:&gt;20	@-FMAINV %VP EN
22	with	with	ha:&gt;21	@ADVL %EH PREP
23	MG132	mg132	pcomp:&gt;22	@&lt;P %NH N NOM SG
24	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
